LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

JNJ

149.61

-2.5%↓

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

JNJ

149.61

-2.5%↓

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

JNJ

149.61

-2.5%↓

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

JNJ

149.61

-2.5%↓

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

LLY

807.28

+0.75%↑

UNH

516.88

-0.82%↓

JNJ

149.61

-2.5%↓

MRK

131.09

+0.02%↑

ABBV

158.36

-0.72%↓

Search

Novo Nordisk A-S

Open

Sector Healthcare

135.68 1.31

Overview

Share price change

24h

Current

Min

135.02

Max

137.19

Key metrics

By Trading Economics

Income

3.1B

22B

Sales

7.1B

66B

P/E

Sector Avg

43.245

23.904

EPS

4.91

Dividend yield

1.128

Profit margin

38.273

EBITDA

3.4B

29B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+10.42 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.13%

7.76%

Market Stats

By TradingEconomics

Market Cap

15B

450B

Previous open

134.37

Previous close

135.68

News Sentiment

By Acuity

25%

75%

47 / 370 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Novo Nordisk A-S Chart

Related News

3 May 2024, 13:51 UTC

Acquisitions, Mergers, Takeovers

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

2 May 2024, 06:58 UTC

Earnings

Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating -- Update

2 May 2024, 06:08 UTC

Top News
Earnings

Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating

21 May 2024, 11:04 UTC

Earnings
Acquisitions, Mergers, Takeovers

Why Jamie Dimon's Buyback Bombshell Is a Warning -2-

21 May 2024, 11:04 UTC

Earnings
Acquisitions, Mergers, Takeovers

Why Jamie Dimon's Buyback Bombshell Is a Warning for Stocks, and 5 Other Things to Know Before the Market Opens -- Barrons.com

13 May 2024, 11:15 UTC

Market Talk
Earnings

Novo Nordisk's Wegovy Supply is Ramping Up -- Market Talk

9 May 2024, 12:00 UTC

Top News

Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled -- WSJ

3 May 2024, 14:43 UTC

Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3 May 2024, 12:31 UTC

Market Talk
Earnings

Novo Nordisk Sentiment Dampened by Wegovy Price Cuts -- Market Talk

3 May 2024, 10:59 UTC

Acquisitions, Mergers, Takeovers

Why Apple's Nascent Rally Could Be Stalled By Warren Buffett, and 5 Other Things to Know Today. -- Barrons.com

3 May 2024, 10:59 UTC

Acquisitions, Mergers, Takeovers

Why Apple's Nascent Rally Could Be Stalled By -2-

2 May 2024, 15:09 UTC

Earnings

Novo Nordisk, ING, Shell: European Stocks in the Spotlight -- WSJ

2 May 2024, 14:16 UTC

Earnings

Novo Nordisk's Wegovy Sales More Than Doubled. Why the Stock Is Falling. -- Barrons.com

2 May 2024, 13:59 UTC

Earnings

Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast -- IBD

2 May 2024, 12:19 UTC

Earnings

Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target -- IBD

2 May 2024, 10:09 UTC

Earnings

Wegovy Sales More Than Double as Demand Soars -- WSJ

2 May 2024, 09:08 UTC

Hot Stocks

Stocks to Watch Thursday: Shell, Novo Nordisk, Apple -- WSJ

2 May 2024, 08:23 UTC

Market Talk

Novo Nordisk Posts 'Low Quality' Earnings Beat, UBS Says -- Market Talk

2 May 2024, 07:53 UTC

Market Talk
Earnings

Novo Nordisk Results Imply Minor Consensus Upgrades -- Market Talk

2 May 2024, 05:41 UTC

Earnings

Novo Nordisk Expects Continued Periodic Supply Constraints and Related Drug Shortage Notifications

2 May 2024, 05:40 UTC

Earnings

Novo Nordisk Expects Continued Volume Growth and Capacity Limitations at Some Manufacturing Sites

2 May 2024, 05:37 UTC

Earnings

Novo Nordisk: US Sales Growth Positively Impacted by Gross-to-Net Sales Adjustments

2 May 2024, 05:36 UTC

Earnings

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Drug Shortage Notifications

2 May 2024, 05:36 UTC

Earnings

Novo Nordisk 1Q Wegovy Drug Sales More Than Doubled on Yr To DKK9.38B

2 May 2024, 05:35 UTC

Earnings

Novo Nordisk 1Q Ozempic Drug Sales +42% on Year To DKK27.81B

2 May 2024, 05:35 UTC

Earnings

Novo Nordisk 1Q Gross Margin 84.8% Vs 84.7%, Op Margin 48.7% Vs 46.9%

2 May 2024, 05:33 UTC

Earnings

Novo Nordisk: 1Q Sales Growth Driven by Increased Demand For GLP-1 Diabetes and Obesity Treatments

2 May 2024, 05:33 UTC

Earnings

Novo Nordisk: Had Seen 2024 Sales Growth of 18%-26%, Op Profit Growth of 21%-29%

2 May 2024, 05:33 UTC

Earnings

Novo Nordisk Now Sees FY Sales Growth at 19%-27%, Op Profit Growth at 22%-30%

2 May 2024, 05:32 UTC

Earnings

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK23.09B

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

10.42% upside

12 Months Forecast

Average 148 USD  10.42%

High 163 USD

Low 130 USD

Based on 7 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

132.92 / 135.16Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

47 / 370 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.